{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.3","upperLimit":"84.4","value":"79.7"},{"groupId":"OG001","lowerLimit":"28.5","upperLimit":"40.3","value":"34.2"}]}],"title":"BICR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"71.2","upperLimit":"82.0","value":"77.0"},{"groupId":"OG001","lowerLimit":"31.0","upperLimit":"43.0","value":"36.9"}]}],"title":"Investigator Assessment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"263"}],"units":"Participants"}],"description":"The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR and investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DM1 in accordance with the approved label.","id":"OG001","title":"Ado-trastuzumab Emtansine (T-DM1)"}],"paramType":"NUMBER","populationDescription":"Objective response rate was assessed in the Full Analysis Set at data cut-off date of 21 May 2021.","reportingStatus":"POSTED","timeFrame":"Up to 33 months (data cut-off)","title":"Percentage of Participants With Objective Response Rate (ORR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}